However, the standard of care (SOC) for BC, including endocrine therapy for estrogen receptor-alpha (ERα) positive, anti-HER2 monoclonal antibody therapy for human epidermal growth factor receptor-2 (HER2) positive, and chemotherapy for TNBC subtypes, often face limitations in clinical practice due to drug tolerance (Waks and Winer, 2019; Barzaman et al., 2020). This evidence concerns the gene ESR1 and breast cancer.